A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Public ClinicalTrials.gov record NCT02017171. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Despite improvements during the past 20 years in blood glucose and blood pressure control, diabetic kidney disease remains one of the most important causes of health problems in patients with diabetes. Novel treatments to complement blood glucose and blood pressure control are urgently needed. The goal of this study is to see whether a medication called allopurinol may help prevent loss of kidney function among people with type 1 diabetes. Allopurinol has been used for many years to decrease high blood uric acid and treat gout - a disease characterized by arthritis, especially of the foot joints. There is evidence suggesting that allopurinol might also be useful in people with diabetes who have normal or moderately impaired kidney function to decrease the risk of developing advanced kidney disease in the future. To prove this beneficial effect of allopurinol, we will be conducting an international clinical trial at eight diabetes centers, enrolling approximately 480 patients with type 1 diabetes who are at increased risk of developing kidney disease. Participants will be randomly assigned to take allopurinol or placebo (inactive pill) for three years, during which they will be followed through periodical visits. To prevent any possible bias, neither the participants nor the clinical staff knows who is taking allopurinol and who is taking the placebo. Kidney function will be measured at the beginning and at the end of the treatment period to see whether patients taking allopurinol experience a slower loss of kidney function over time as compared to those taking the inactive pill. If this trial is successful, the reduction in health problems resulting from the prevention or delay of kidney function loss due to the use of allopurinol would have a major impact on the lives of type 1 diabetic patients as well as on society at large, significantly reducing the human and financial costs associated with diabetic kidney disease. Because of the emphasis on early intervention, the proposed trial, if successful, will establish a new paradigm in treatments to slow or prevent progression towards end stage kidney disease in type 1 diabetes far beyond anything achieved to date.
Study identification
- NCT ID
- NCT02017171
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 530 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2014
- Primary completion
- Jul 14, 2019
- Completion
- Aug 30, 2019
- Last update posted
- Dec 3, 2020
2014 – 2019
United States locations
- U.S. sites
- 23
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barbara Davis Center / University of Colorado Denver | Aurora | Colorado | 80045 | — |
| Kaiser Permanente Colorado Institute of Health Research | Denver | Colorado | 80231 | — |
| Emory University - Grady Memorial Hospital | Atlanta | Georgia | 30303 | — |
| Atlanta Diabetes Associates | Atlanta | Georgia | 30318 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Joslin Diabetes Center | Boston | Massachusetts | 02215 | — |
| University of Massachusetts Memorial Health Care | Worcester | Massachusetts | 01655 | — |
| Brehm Center for Diabetes Research / University of Michigan | Ann Arbor | Michigan | 48105 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Winthrop-University Hospital | Mineola | New York | 11501 | — |
| ICAHN School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Weill Cornell Medical Center | New York | New York | 10065 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Albert Einstein College of Medicine / Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Jacobi Medical Center | The Bronx | New York | 10461 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| University of Washington | Seattle | Washington | 98105 | — |
| Providence Sacred Heart Medical Center | Spokane | Washington | 99204 | — |
| Gunderson Health System | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02017171, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2020 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02017171 live on ClinicalTrials.gov.